Caritas Therapeutics

After the gene therapy business of Amicus Therapeutics, Inc., a rare disease drug developer, was acquired by SPAC company ARYA Sciences Acquisition Corp IV, Caritas Therapeutics, Inc., a next-generation genetic medicine company, was established. Caritas Therapeutics, Inc. is a next-generation genetic drug developer focused on the discovery and development of clinical-stage treatments for rare diseases.